Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 12;8(4):300-303.
doi: 10.15420/aer.2019.30.2.

Ivabradine and AF: Coincidence, Correlation or a New Treatment?

Mahmoud Abdelnabi  1 , Ashraf Ahmed  2 , Abdallah Almaghraby  2 , Yehia Saleh  2   3 , Haitham Badran  4
Affiliations
Review

Ivabradine and AF: Coincidence, Correlation or a New Treatment?

Mahmoud Abdelnabi et al. Arrhythm Electrophysiol Rev. .

Abstract

Ivabradine is a heart rate-lowering agent that inhibits pacemaker funny current (If). It has been approved by the European Medicines Agency and the US Food and Drug Administration for patients with stable angina and heart failure (HF). AF is a common issue especially in ischaemic heart disease and HF patients. In contrast to experimental findings and a limited number of clinical trials that demonstrate the emerging role of ivabradine for heart rate control in AF or maintenance of sinus rhythm, there is accumulating contradictory data indicating that there is, in fact, an increased incidence of new-onset AF among people who are taking ivabradine in clinical practice. This article reviews the most recent evidence highlighting the diversity of data in relation to the use of ivabradine and the onset of AF and whether it has a legitimate role in AF treatment and the maintenance of sinus rhythm.

Keywords: AF; If channels; If current; Ivabradine; acute coronary syndromes; angina; heart failure; heart rate.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Mechanism of Action of Ivabradine
See this image and copyright information in PMC

References

    1. Koruth JS, Lala A, Pinney S et al. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70:1777–84. doi: 10.1016/j.jacc.2017.08.038. - DOI - PubMed
    1. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53:399–406. doi: 10.1016/j.phrs.2006.03.006. - DOI - PubMed
    1. Dyer AR, Persky V, Stamler J et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112:736–49. doi: 10.1093/oxfordjournals.aje.a113046. - DOI - PubMed
    1. Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987;113:1489–94. doi: 10.1016/0002-8703(87)90666-1. - DOI - PubMed
    1. Ponikowski P, Voors A, Anker S et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200. doi: 10.1093/eurheartj/ehw128. - DOI - PubMed